Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.35 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | IDUA | P35475 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 2/20 | 0.30 |
| ▸ | SELL | P14151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26031680 | 1.00 | FUCA1 (0.35) | FUCA1SELECA9IDUACA12 | |
| SCHEMBL27405478 | 0.88 | IDUA (0.30) | IDUA | |
| SCHEMBL16773473 | 0.78 | FUCA1 (0.35) | FUCA1 | |
| SCHEMBL26194052 | 0.78 | FUCA1 (0.35) | FUCA1 | |
| SCHEMBL19129670 | 0.78 | FUCA1 (0.35) | FUCA1 | |
| SCHEMBL9914020 | 0.77 | FUCA1 (0.40) | FUCA1CA9IDUACA12CA2 | |
| SCHEMBL14025396 | 0.77 | FUCA1 (0.40) | FUCA1CA9IDUACA12CA2 | |
| SCHEMBL9914017 | 0.77 | FUCA1 (0.40) | FUCA1CA9IDUACA12CA2 | |
| SCHEMBL9915194 | 0.77 | FUCA1 (0.40) | FUCA1CA9IDUACA12CA2 | |
| SCHEMBL20161471 | 0.77 | FUCA1 (0.40) | FUCA1CA9IDUACA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218366-A1 | COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-07-04 | — | — | US | disclosed |
| US-20240209369-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-06-27 | — | — | US | disclosed |
| US-20240018515-A1 | COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-01-18 | — | — | US | disclosed |
| US-20230332147-A1 | IRNA COMPOSITIONS AND METHODS FOR SILENCING GROWTH FACTOR RECEPTOR BOUND PROTEIN 10 (GRB10) OR GROWTH FACTOR RECEPTOR BOUND PROTEIN 14 (GRB14) IN THE LIVER | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230323357-A1 | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | BANK OF AMERICA, N.A. | 2023-09-28 | — | — | US | disclosed |
| US-20230257749-A1 | COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-20230220396-A1 | TRANSMEMBRANE PROTEASE, SERINE 6 (TMPRSS6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-07-13 | — | — | US | disclosed |
| US-20230203496-A1 | SIRNA COMPOSITIONS AND METHODS FOR SILENCING GPAM (GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1, MITOCHONDRIAL) EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230183706-A1 | COMPOSITIONS AND METHODS FOR TREATING SUBJECTS HAVING A HETEROZYGOUS ALANINE-GLYOXYLATE AMINOTRANSFERASE GENE (AGXT) VARIANT | BANK OF AMERICA, N.A. | 2023-06-15 | — | — | US | disclosed |
| US-20230183701-A1 | Modified Double-Stranded RNA Agents | BANK OF AMERICA, N.A. | 2023-06-15 | — | — | US | disclosed |
| US-20230133637-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-05-04 | — | — | US | disclosed |
| US-20230125933-A1 | MANNAN BINDING LECTIN SERINE PEPTIDASE 2 (MASP2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230126881-A1 | Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183706-A1 | COMPOSITIONS AND METHODS FOR TREATING SUBJECTS HAVING A HETEROZYGOUS ALANINE-GLYOXYLATE AMINOTRANSFERASE GENE (AGXT) VARIANT | AGXT, HAO1, HAAO | FUCA1 245/4885SELE 4767/4885CA9 292/4885 |
| US-20230323357-A1 | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | TRAF6, TRAF2, TNFRSF1A | FUCA1 2072/4885SELE 4680/4885CA9 4101/4885 |
| US-20230220396-A1 | TRANSMEMBRANE PROTEASE, SERINE 6 (TMPRSS6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | TMPRSS6, TMPRSS4, RNASE1 | FUCA1 1581/4885SELE 2349/4885CA9 3324/4885 |
| US-20240218366-A1 | COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | F5, F13B, F12 | FUCA1 334/4885SELE 2182/4885CA9 4208/4885 |
| US-20230257749-A1 | COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | CFB, CFH, RNASE1 | FUCA1 162/4885SELE 2660/4885CA9 3561/4885 |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | TTR, MTPN, CRYAA | FUCA1 277/4885SELE 3862/4885CA9 2485/4885 |
| US-20230203496-A1 | SIRNA COMPOSITIONS AND METHODS FOR SILENCING GPAM (GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1, MITOCHONDRIAL) EXPRESSION | POLRMT, ACAT1, GPAA1 | FUCA1 1795/4885SELE 4774/4885CA9 3516/4885 |
| US-20240018515-A1 | COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | CFB, CFH, RNASE1 | FUCA1 162/4885SELE 2660/4885CA9 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.